Hemostasis parameters disturbances in healthy individuals with prehypertension

Clinical and Experimental Hypertension

Volumn 34, Issue 6, 2012, Pages 385-388

  Papadopoulos, Dimitris ^a   Mourouzis, Iordanis ^a   Kotrotsou, Athanasia ^a   Papazachou, Urania ^b   Sanidas, Elias ^a   Tsioufis, Kostas ^c   Makris, Thomas ^b  

^a LAIKO GENERAL HOSPITAL   (Greece)

^b HELENA VENIZELOU HOSPITAL   (Greece)

^c UNIVERSITY OF ATHENS   (Greece)

Author keywords

Fibrinogen; Hypertension; Plasminogen activator inhibitor 1; Prehypertension; Thrombomodulin; Tissue plasminogen activator

Indexed keywords

FIBRINOGEN; LIPID; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGE; ARTICLE; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PH; PREHYPERTENSION; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE;

BLOOD PRESSURE; FEMALE; FIBRINOGEN; HEMOSTASIS; HUMANS; HYPERTENSION; LIPIDS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREHYPERTENSION; RISK FACTORS; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84866138785     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.3109/10641963.2011.631650     Document Type: Article

References (24)

1. Vasan RS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001; 345(18):1291-1297.
2. Lip G, Blann A, Jones A, Lip P, Beevers D. Relation of endothelium, thrombogenesis, and hemorheology in systemic hypertension to ethnicity and left ventricular hypertrophy. Am J Cardiol 1997; 80:1566-1571. (Pubitemid 28011832)
3. Eliasson M, Jansson J, Nilsson P, Asplund K. Increased levels of tPA-Ag in essential hypertension. A popular-based study in Sweden. J Hypertens 1997; 15:349-356. (Pubitemid 27187137)
4. Phillips GB, Jing T-Y, Resnick LM, Barbagallo M, Laragh JH, Sealey JE. Sex hormones and haemostatic risk factors for coronary heart disease in men with hypertension. J Hypertens 1993; 11:699-702. (Pubitemid 23254405)
5. Makris T, Tsoukala C, Krespi P, et al. Haemostasis balance disorders in patients with essential hypertension. Thromb Res 1997; 88:99-107. (Pubitemid 27486406)
6. Meade TW, Mellows S, Brozovic M, et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; 2:533-537. (Pubitemid 16054632)
7. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342:1076-1079. (Pubitemid 23338739)
8. Coban E, Ozdogan M. The plasma levels of plasminogen activator inhibitor-1 in subjects with white coat hypertension. Int J Clin Pract 2004; 58:541-544. (Pubitemid 38996979)
9. Coban E, Ozdogan M, Akcit F. Levels of plasma fibrino-gen and D-dimmer in subjects with white-coat hypertension. J Hum Hypertens 2004; 18:291-292. (Pubitemid 38499885)
10. Kario K, Matsuo T, Kobayashi H, et al. Factor VII hyper-activity and endothelial cell damage are found in elderly hypertensives only when concomitant with microalbuminuria. Arterioscler Thromb Vasc Biol 1996; 16:455-461. (Pubitemid 26084321)
11. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289(19):2560-2572.
12. Seidell JC, Cigolini M, Deslypere JP, Charzewska J, Ellsinger B, Cruz B. Body fat distribution in relation to physical activity and smoking habits in 38-year old European men. Am J Epidemiol 1991; 133:257-265.
13. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21(6):1011-1053.
14. Blann AD, Amiral J, McCollum CN. Prognostic value of increased soluble thrombomodulin and increased soluble E-selectin in ischaemic heart disease. Eur J Haematol 1997; 59:115-120. (Pubitemid 27357476)
15. Makris T. Thrombomodulin levels in patients with arterial hypertension. Am J Med 1997; 103:331-332. (Pubitemid 27459261)
16. Blann AD, Seigneur M, Steiner M, Boisseau MR, McCollum CN. Circulating endothelial markers in peripheral vascular disease: relationship to the location and extent of atherosclerotic disease. Eur J Clin Invest 1997; 27:916-921. (Pubitemid 27483525)
17. Makris T, Stavroulakis G, Papadopoulos D, et al. White coat hypertension and haemostatic/fibrinolytic balance disorders. Eur Cytokine Netw 2006; 17(2):137-141.
18. Zorio E, Gilabert-Estellés J, España F, Ramón LA, Cosín R, Estellés A. Fibrinolysis: the key to new pathogenetic mechanisms. Curr Med Chem 2008; 15(9):923-929. (Pubitemid 351736413)
19. Knier B, Cordasic N, Klanke B, et al. Effect of the plasminogen-plasmin system on hypertensive renal and cardiac damage. J Hypertens 2011; 29(8):1602-1612.
20. Wall U, Jern C, Bergbrant A, Jern S. Enhanced levels of tPA in borderline hypertension. Hypertension 1995; 26: 796-800.
21. Lemne C, Faire U. Elevation of PAI-1 in borderline hypertension is linked to concomitant metabolic disturbances. Eur J Clin Invest 1996; 26:692-697. (Pubitemid 26273719)
22. Endre T, Mattiason I, Berntorp E, Berglund G, Hulten L. Coagulation and fibrinolytic factors in normotensive hypertensive prone men. J Hypertens 1996; 14:629-634. (Pubitemid 26161118)
23. Makris T, Stavroulakis G, Hatzizacharias A, et al. Increased heart rate and haemostatic balance disorders pre-exist the established hypertension. Thromb Haemost 1999; 81: 664-665. (Pubitemid 29178964)
24. Makris T, Stavroulakis G, Dafni U, et al. ACE DD genotype is associated with haemostasis balance disturbances reflecting hypercoagulability and endothelial dysfunction in untreated hypertensives. Am Heart J 2000; 140: 760-765.